Actinium Pharmaceuticals filings document governance and public-company reporting for a biopharmaceutical issuer whose common stock is registered on the NYSE American under ATNM. Recent Current Reports and proxy materials cover annual meeting matters, Class III director elections, advisory votes on executive compensation, principal financial officer changes, and registered common stock details.
The company's proxy disclosures connect shareholder voting matters with board structure, compensation oversight, and annual-report materials. Form 8-K filings record material events and amendments to prior event reports, including officer-transition disclosures and the final reporting of annual meeting voting outcomes.
Actinium Pharmaceuticals, Inc. (ATNM) reported that Chief Executive Officer and director Sandesh Seth received significant equity awards on September 2, 2026. He was granted stock options to acquire 1,130,400 shares of common stock at an exercise price of $1.00 per share, vesting in fifty equal monthly tranches and expiring on September 2, 2036. He also received 753,600 restricted stock units that vest in three equal annual installments and 1,027,274 restricted stock units that vest fully on the third anniversary of the grant date. No Rule 10b5-1 trading plan is reported for these awards.
Actinium Pharmaceuticals, Inc. (ATNM) reported that director Richard I. Steinhart received equity awards on September 2, 2026. He was granted 62,800 shares of Common Stock in the form of restricted stock units that vest in three equal annual installments over three years, resulting in 63,116 Common shares held directly after the grant. He also received a stock option for 94,200 shares of Common Stock at an exercise price of $1.00 per share, vesting in fifty equal monthly tranches and expiring on September 2, 2036. No Rule 10b5-1 trading plan is reported for these awards.
Actinium Pharmaceuticals, Inc. (ATNM) director Jeffrey W. Chell received equity awards on September 2, 2026, consisting of 61,600 shares of Common Stock in the form of restricted stock units and 92,400 stock options with a $1.00 exercise price expiring September 2, 2036. The RSUs vest in three equal annual installments, while the options vest in fifty equal monthly tranches beginning on the grant date. No Rule 10b5-1 trading plan is reported.
Actinium Pharmaceuticals, Inc. reports that NYSE Regulation has accepted its compliance plan, granting a plan period through November 27, 2027 to regain compliance with NYSE American continued listing standards under Sections 1003(a)(ii) and 1003(a)(iii). During this period, the common stock will continue to trade on NYSE American under the symbol ATNM, subject to ongoing compliance with other listing requirements and periodic NYSE review. Failure to regain compliance or demonstrate satisfactory progress may lead to delisting proceedings.
Actinium also highlights advances in its Actimab-A radiotherapy program, including multiple newly issued and allowed patents in the United States and internationally, with terms extending into 2037–2043, covering uses in AML, MDS and solid tumors via myeloid-derived suppressor cell targeting. The company has amended its IND to add an additional manufacturer to support studies under its CRADA with the National Cancer Institute and company-sponsored trials, aiming to expand manufacturing capacity as clinical milestones approach from late 2026 into 2027. Actinium states it has about 250 patents and patent applications across its portfolio.
Actinium Pharmaceuticals reported a sharp swing to profitability for the quarter ended June 30, 2026 after recognizing previously deferred license revenue. Total revenue was $35.0 million, all from Immedica Pharma’s upfront payment under the Iomab‑B license, driving net income of $27.9 million, or $0.89 per diluted share, versus a $6.9 million loss a year earlier. For the first six months of 2026, revenue was $35.0 million and net income was $22.4 million, compared with a $22.8 million loss in the prior‑year period.
Despite the accounting profit, operations used $11,049 thousand of cash in the first half, and cash, cash equivalents and restricted cash declined to $36,812 thousand from $48,333 thousand at year‑end 2025. Total liabilities fell to $9,855 thousand as the $35.0 million long‑term license revenue deferred balance was eliminated, increasing stockholders’ equity to $30,302 thousand. Research and development expenses were $9,578 thousand and general and administrative expenses $3,760 thousand for the six‑month period. The company highlights a broad radiotherapy pipeline, including ATNM‑400 for solid tumors, Actimab‑A for AML, MDS and immuno‑oncology combinations, and CD45‑targeted conditioning agents Iomab‑B and Iomab‑ACT, with multiple data readouts expected from late 2026 into 2027.
Actinium Pharmaceuticals, Inc. has submitted a compliance plan to NYSE American after being notified it is not meeting certain continued listing standards. The exchange requires stockholders’ equity of at least $4.0 million when a company has recorded losses in three of its four most recent fiscal years.
The plan outlines actions management intends to take to restore compliance and maintain the company’s NYSE American listing status. The filing does not detail the specific steps but confirms the plan was delivered on June 18, 2026, in response to the prior deficiency notice.
Actinium Pharmaceuticals received a notice from NYSE American that it is not in compliance with continued listing standards because its stockholders’ equity was approximately $2.3 million as of March 31, 2026, below the required $4.0 million minimum and after reporting net losses in its last five fiscal years. The company must submit a plan by June 26, 2026 to regain compliance by November 27, 2027, or it may face delisting, though its shares will continue trading on NYSE American under the symbol ATNM with a “.BC” below-compliance indicator. Actinium intends to submit a plan and, separately, plans to present new preclinical data for its ATNM-400 radioconjugate program and related pipeline candidates at the SNMMI 2026 conference.
Actinium Pharmaceuticals, Inc. files its annual report describing a clinical‑stage radiopharmaceutical business focused on targeted radiotherapies for solid tumors and blood cancers. Lead programs include ATNM‑400 for prostate, lung and breast cancer, Actimab‑A for myeloid malignancies and immuno‑oncology, and conditioning agents Iomab‑B and Iomab‑ACT for transplants and cell therapies.
The company highlights extensive preclinical data, late‑stage hematology assets with FDA‑aligned Phase 2/3 designs, and plans for a cGMP manufacturing facility expected operational in the second half of 2026. Actinium reports a net loss of $33.9 million in 2025, an accumulated deficit of $409.7 million, and 31,374,994 common shares outstanding as of March 30, 2026.
Actinium Pharmaceuticals, Inc. filed an amendment to update its prior report on the results of its Annual General Meeting. Shareholders had indicated a preference for holding an advisory vote on executive compensation (“Say-on-Pay”) every year.
On March 20, 2026, the board of directors decided that future Say-on-Pay votes will be conducted annually, aligning with the shareholder preference. The board plans to re-evaluate this approach after the next shareholder advisory vote on Say-on-Pay frequency, which is expected at the 2031 Annual General Meeting of Shareholders, unless considered earlier.